Emerging systemic therapies in rare urothelial cancer variants

Lenvatinib plus pembro for aRCC - update on the CLEAR study

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC

RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy

A new era of early cancer detection with blood test may change cancer screening paradigms

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma